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Abstract: Postpartum depression (PPD) is a common complication of childbearing, and has 
increasingly been identified as a major public health problem. Untreated maternal depression 
has multiple potential negative effects on maternal-infant attachment and child development. 
Screening for depression in the perinatal period is feasible in multiple primary care or obstetric 
settings, and can help identify depressed mothers earlier. However, there are multiple barriers to 
appropriate treatment, including concerns about medication effects in breastfeeding infants. This 
article reviews the literature and recommendations for the treatment of postpartum depression, 
with a focus on the range of pharmacological, psychotherapeutic, and other nonpharmacologic 
interventions. 
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Introduction
epidemiology of postpartum depression
Estimates of prevalence of PPD in the US, UK and Australia range from 7%–20%, 
with most studies suggesting rates between 10%–15%.6,7 Significant risk factors 
for PPD include a history of depression prior to or during pregnancy, anxiety dur-
ing   pregnancy, experiencing stressful life events during pregnancy or the early 
  puerperium, low levels of social support8 or partner support,9 low socioeconomic 
status, and obstetric complications.7 Although mental health often is not prioritized 
as a problem in poorer countries where access to basic nutrition and health care are 
not consistent, the evidence suggests that postnatal depression may be both more 
common and more grave for women and their children in low-income countries. The 
limited data from resource-constrained countries suggests that rates of depression 
in mothers of young infants exceeds 25%,10 and in some settings may be as high as 
60%.11 The intersection of cultural, interpersonal and socioeconomic factors may 
also confer significant risk of PPD: in one study in Goa, India, risk for depression 
after delivery increased with economic deprivation, marital violence, and female 
gender of the infant.12
Negative effects of maternal depression
Untreated maternal depression is associated with serious morbidity for the mother, 
the infant, and the family system. Perinatal depression causes significant suffering in 
women at a time when personal or societal notions of motherhood as a uniquely joyful, International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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if tiring, experience may be incongruous with the depressed 
woman’s ability to feel gratification in the mothering role,13 
connect with her infant, or carry out the often overwhelm-
ing tasks of caring for a new baby.14 Such a disconnect can 
reinforce the disabling sense of isolation, guilt, helplessness 
and hopelessness that frequently characterize the depressed 
state. Women with PPD are at higher risk for smoking,15 
alcohol or illicit substance abuse,16 and are more likely 
than nondepressed mothers to   experience current or recent 
physical, emotional, or sexual abuse. Although rates of sui-
cide for women during pregnancy and the puerperum are 
lower than the general   population, suicide is an important 
cause of maternal mortality.17   Self-inflicted injury is the 
leading cause of one-year maternal mortality in the United 
Kingdom.18 A recent World Health Organization report 
on women’s health identifies self-inflicted injury as the 
second leading cause of maternal mortality in high-income 
countries; suicide remains an important cause of maternal 
deaths in moderate and low-income countries.19 Intrusive 
thoughts of accidental or intentional harm to the baby are 
common in the early postpartum time.20 These thoughts are 
more frequent and distressing in women with postpartum 
depression;21 however, nonpsychotic depressed women are 
unlikely to commit infanticide.22
The adverse impact of maternal depression on infant 
outcomes has also been studied. Depression has   significant 
  negative effects on a mother’s ability to interact   appropriately 
with her child.13 Depressed women have been found to have 
poorer responsiveness to infant cues23 and more negative, hos-
tile or disengaged parenting behaviors.24 These   disruptions 
in maternal-infant interactions have been   associated with 
lower cognitive functioning and adverse emotional devel-
opment in children, and they appear to be universal across 
cultural and economic divides.25,26 Other parenting   behaviors 
are also affected, including problematic sleep habits, 
lower   preventative health care utilization and undesirable 
safety practices.26 Chronic depression in   mothers places 
children at higher risk for behavioral problems27 and later 
  psychopathology, including anxiety, disruptive, and affective 
disorders; conversely, remission of depression in mothers is 
associated with reduction or remission in the children’s psy-
chiatric diagnoses.28 Maternal depression also increases the 
risk for negative infant feeding outcomes, including lower 
rates of initiating or maintaining breastfeeding, lower levels 
of breastfeeding self-efficacy, and more difficulties while 
breastfeeding.29 In low-income countries, maternal depres-
sion has been associated with both malnutrition and higher 
rates of diarrheal illness in children.30
Diagnosis of postpartum depression
The diagnostic criteria for a Major Depressive Episode 
(MDE) as defined by the Diagnostic and Statistical Manual 
(DSM-IV) do not differ in the postpartum period as   compared 
to other times, and include at least 2 weeks of persistent 
low mood or anhedonia, as well as at least four of the 
  following: increased or decreased appetite, sleep disturbance, 
  psychomotor agitation or retardation, low energy, feelings 
of   worthlessness, low concentration, and suicidal ideation.31 
A MDE may be classified as having a postpartum onset if 
the depressive symptoms begin within the first 4 weeks 
after delivery. However, studies suggest that depressive epi-
sodes are significantly more common in women in the first 
three months after delivery,32 and an increased   vulnerability 
to   psychiatric illness may persist for a year or more.33 It is 
important to differentiate PPD from other psychiatric and 
nonpsychiatric diagnoses. The “postpartum blues” or “baby 
blues” is a transient mood disturbance that affects up to 75% 
of new mothers in the 10 days following delivery, and consists 
of crying, irritability, fatigue, anxiety, and emotional lability. 
Symptoms are generally mild and self-limited, and do not 
involve total loss of pleasure or interest, persistent low mood, 
or suicidal ideation.34 On the other extreme, postpartum 
psychosis is a psychiatric emergency that requires   immediate 
intervention, and is characterized by the rapid onset of severe 
mood swings, a waxing and waning sensorium, delusions, 
hallucinations or disorganized behaviors, and a relatively 
high incidence of suicidal ideation or homicidal ideation 
toward the infant.35 Women presenting with a depressive 
episode, mood elevation, or psychotic symptoms should 
be screened for any prior history of mania or hypomania to 
rule out previously undiagnosed bipolar   disorder.36 Anxiety 
disorders are common in perinatal women, and women 
may have depression comorbid with obsessive-compulsive 
symptoms, generalized anxiety disorder, panic disorder or 
post-traumatic stress disorder.37 Substance use and medical 
causes of psychiatric symptoms, such as thyroid disorders, 
should also be considered.
Screening for postpartum depression
To try to mitigate these serious adverse outcomes of PPD, 
there has been increasing focus on the importance of 
early and accurate detection and treatment of depression 
after or during pregnancy.38 Identification of depression 
in the   postpartum period may be complicated by some 
of the   normal   physical and emotional demands of new 
  motherhood, including changes in energy and appetite, sleep 
  deprivation, and   heightened concern for the infant. Experts International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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have   recommended screening for PPD at the first postnatal 
obstetrical visit   (usually 4–6 weeks after delivery),39 or in the 
family practice40 or pediatric setting,41 as these are the most 
widespread points of interaction with the health care system 
for new mothers within the first three months of delivery. The 
most commonly used screening tool for PPD is the Edinburgh 
Postnatal Depression Scale (EPDS),42 a 10-item self-report 
that emphasizes emotional and functional factors rather than 
somatic symptoms. Although variability in sensitivity and 
specificity occurs across languages and cultures,11,43 a reason-
able cutoff for a positive screen on the EPDS is $13 (out of 
a possible 30), though special note should be made of any 
positive responses to Item 10 assessing suicidal ideation.39,43 
Other commonly used screening tools with evidence of 
validity in the puerperium include the Postpartum Depression 
Screening Scale (PDSS),44 as well as the 9-item Physician’s 
Health Questionnaire (PHQ-9).45 It should be emphasized 
that these instruments are screening tools which will generate 
a certain number of false-positives; diagnosis of depression 
must be confirmed by clinical interview.
Discusssion
Pharmacological treatments  
for postpartum depression
Antidepressant medication
A small but growing literature suggests that postpartum 
depression can be thought of as a variant of major depression 
that responds similarly to antidepressant medication.46,47 
Concerns unique to pharmacologic treatment of PPD include 
metabolic changes in the postpartum period, exposure of the 
infant to medication in breast milk, the effect of depression 
and treatment on the ability of the depressed mother to care for 
a new baby, and the perceived stigma of being seen as a “bad 
mother” for requiring medication.48–50 These factors, as well as 
the woman’s level of distress, access to care, and experience 
with past treatment may influence the decision of the patient 
and her caregiver regarding the choice of pharmacologic and 
nonpharmacologic treatments for PPD. Data comparing the 
effectiveness of medication against other treatment modalities 
for PPD are scarce, though do suggest that medications are at 
least as effective as most psychological interventions based on 
effect size.51 To date, four randomized controlled studies on 
the treatment of PPD with antidepressant medications have 
been published, along with several open trials. Additionally, 
two randomized studies have looked at the prevention of PPD 
with antidepressant medication.
In a study of 87 women with major or minor depression 
in the postpartum period, subjects were randomized to 
one of four groups receiving either fluoxetine or placebo 
plus one or six cognitive behavioral therapy (CBT) based 
counseling sessions.52 Breastfeeding mothers were excluded 
from the study. Improvement was seen in all groups, with 
greater reduction in depression severity in the fluoxetine 
group compared to the placebo medication, and greater 
improvement with six counseling sessions compared to one 
session. Women receiving both fluoxetine and counseling 
did not differ significantly in outcome compared to women 
who received fluoxetine alone. Because the mean baseline 
level of depressive symptoms based on rating scales was 
mild, the findings are not easily generalized to a population 
with more severe postpartum depression.
A subsequent study randomized 35 women with postpar-
tum depression and comorbid anxiety to receive paroxetine 
or paroxetine plus CBT for 12 weeks.53 Both groups showed 
significant improvement in depressive and anxiety symptoms 
(response rates 87.5% in the paroxetine group and 78.9% in 
the combined group) without significant differences between 
groups. The study did not include a placebo arm, making 
analysis of the specific effects of either intervention difficult. 
A third study compared paroxetine to placebo in an 8-week 
randomized controlled trial.54 The attrition rate in this study 
was high, with only 31 of 70 participants completing the 
study (17 in the paroxetine arm and 14 in the placebo arm), 
but the authors found lower mean severity scores and a higher 
remission rate after 8 weeks of treatment with paroxetine 
compared to placebo.
Very few studies have compared different classes of medi-
cations used in postpartum depression. One comparative study 
found treatment with nortriptyline to yield similar outcomes 
as treatment with sertraline.55 After 8 weeks of treatment in 
this large, randomized, double-blind trial, both groups showed 
improvement, and response rates (nortriptyline 69%, sertraline 
56%), remission rates (nortriptyline 48%, sertraline 46%) and 
side effect burden were similar between groups at week 4, 
8 and 24, though side effect profiles differed. There was no 
placebo arm. The response rate could be predicted earlier 
in the group receiving sertraline, but the overall response 
rates were equivalent. Sub-analyses of this study revealed an 
improvement in maternal role function56 and sexual function57 
that was equivalent in both groups.
Several open studies have found sertraline,58 venlafaxine,59 
nefazodone,60 fluvoxamine,61 and bupropion62 to be effective 
in the treatment of postpartum depression. These studies have 
been small, with 4–15 participants, lacked control groups, 
and in several cases were sponsored by the pharmaceutical 
companies manufacturing the studied drug. Though there is International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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little data comparing medications to placebo in the perinatal 
population, taken together, data from both the controlled and 
open studies suggest that antidepressants typically used to 
treat major depression are equally effective in postpartum 
depression, without clear differences between medications 
in efficacy and side effect burden. Therefore, some experts 
recommend that if a patient has responded to a specific 
antidepressant in the past, that medication should be among 
the first to be considered in treating her depression in the 
postpartum.63
Two placebo-controlled studies have looked at the role 
of medication in preventing recurrent PPD. In one small 
randomized placebo controlled pilot study, sertraline initiated 
shortly after birth for nondepressed women with at least 
one prior episode of PPD was found to prevent recurrence 
and prolong time to relapse.64 However, in another study, 
no difference was found in rates of recurrence or time to 
relapse between patients receiving nortriptyline and patients 
receiving placebo: one out of four women in both groups 
suffered a relapse within the 20-week study period.65 Further 
research is needed to conclude whether initiation of antide-
pressants after childbirth in a select group of high risk women 
is preventative against postpartum depression.
Breastfeeding considerations
The benefits of breastfeeding have been well described66–73 
and have led the World Health Organization, the American 
Academy of Pediatrics and the American Academy of Fam-
ily Practitioners to recommend breastfeeding for at least 
the first 6 months for most women.66,67,73 Potential effects of 
antidepressant medication on breastfeeding are of concern to 
many mothers and clinicians.49,74 Neonates and young infants 
are especially vulnerable to potential drug effects due to their 
immature hepatic and renal systems, immature blood–brain 
barriers, and developing neurological systems.75,76 Because 
relatively little is known about the effects of antidepressant 
medication in breast milk, some experts have recommended 
nonpharmacologic treatment modalities when possible, par-
ticularly for mild to moderate depression.76 However, non-
pharmacologic treatments are not effective for some women, 
and may not be accessible for many women.
Information about the effects on infants of exposure to anti-
depressants through breast milk is limited to case reports and 
small studies, with little prospective data.77,78 Several reviews 
of the pooled available data on antidepressant medication 
and breastfeeding have concluded that among the seroton-
ergic reuptake inhibitors (SSRIs), sertraline and paroxetine 
are least likely to be detectable in infant plasma, and have 
been associated with rare, if any, adverse events in infants, 
whereas fluoxetine and citalopram appear to have higher pas-
sage through breast milk.75,79–81 Individual cases of suspected 
adverse effects that have been reported in infants of breastfeed-
ing mothers on antidepressant medications have ranged from 
mild to more serious, and include sleep changes, gastrointesti-
nal problems, respiratory problems, and seizure. In most cases, 
reported effects have been mild and resolved with cessation 
of the medication or breastfeeding. These adverse events have 
been reported in the context of mothers taking citalopram, 
escitalopram, fluoxetine, doxepin and bupropion,79–81 though 
rates and causality are difficult to assess from case reports, 
and other studies have reported no adverse effects with the 
same medications. Given the lower infant blood levels and 
fewer adverse reports, paroxetine or sertraline may be the most 
prudent choice for a patient who is naïve to antidepressant 
medication prior to the postpartum episode. However, adverse 
events have not been definitively linked to elevated plasma 
levels in infants; conversely, there is little data to suggest that 
undetectable levels of antidepressant medication ensure infant 
safety in the long term. In an effort to determine whether 
even low-level SSRI exposure through breast milk has central 
effects in infants, Epperson and colleagues found in separate 
studies that while sertraline and fluoxetine had the expected 
significant effects on the platelet 5-HT transporter of mothers 
taking the medication, their breastfed infants did not experi-
ence a significant change in 5-HT platelet transporters.82,83 
Whether the lack of effect on peripheral transporters can be 
extrapolated to predict no effects in the central nervous system 
of infants remains unclear, though the results are encouraging. 
Among tricyclic antidepressants, nortriptyline has the most 
data supporting safety during breastfeeding, whereas doxepin 
is considered relatively contraindicated.80,82 Information on the 
newer antidepressant medications is sparse, but few adverse 
effects have been reported.80
The long-term risks of low-level exposure to antidepres-
sant medication in breast milk are largely unknown. The 
risks of untreated maternal depression are well-known and 
significant. Some experts recommend that if medication 
treatment is indicated, clinical factors such as the patient’s 
prior response or nonresponse to an individual medication 
rather than data on blood levels should take precedence in the 
choice of first-line agent.75,84 Decisions about initiating anti-
depressant medication during breastfeeding and the choice 
of agent must be made on a case-by-case basis, and should 
involve a discussion of clinical factors, including severity 
of the depressive symptoms and prior response to medica-
tions and/or psychotherapy, known and unknown risks of the International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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medication, the known risks of under- or untreated depres-
sion, and the patient’s preferences.85 Regardless of which 
antidepressant medication a breastfeeding mother takes, the 
infant’s pediatrician should be made aware of the possible 
exposure, and the infant should be monitored for changes in 
feeding patterns, sleeping patterns, sedation, irritability and 
other signs of drug toxicity. As blood levels have not been 
correlated with adverse effects, routine laboratory testing of 
infant blood levels is not currently recommended.
Hormone therapy
There is a dramatic drop in maternal levels of estrogen 
and progesterone at the time of delivery, and this shift 
has been proposed as one trigger for the onset of PPD in 
some women. Effects of estrogen in the brain include the 
promotion of neuronal growth and survival, enhancement 
of neurotransmitter activity, mitigation of oxidative stress 
and modulation of the hypophyseal-pituitary axis.86 A study 
designed to replicate the hormonal changes experienced 
around the time of birth found that women with a prior history 
of postpartum depression experienced mood symptoms when 
exposed to a drop in estradiol and progesterone, whereas 
women without a history of PPD did not.87 This finding 
suggests vulnerability to hormone shifts in a subset of the 
population, and raises the possibility of hormonal interven-
tion as a treatment or preventative intervention for PPD.
In a double-blind placebo-controlled study by Gregoire et al 
61 women with postpartum depression were randomized to 
receive estrogen or placebo patches.88 Breastfeeding women 
were excluded. Over the first month of treatment, women 
receiving estrogen showed greater and more rapid improvement 
in their symptoms as measured on the Edinburgh Postnatal 
Depression Scale and in clinical interviews. Women in the 
placebo group also improved, but maintained depression scores 
above the screening threshold. Neither group had complete 
remission of symptoms. The authors did not control for women 
receiving concomitant antidepressant medication, which was 
more common in the estrogen treatment group, making inter-
pretation of the study results   difficult. Additionally, women 
were included in the study up to 18 months postpartum, by 
which time the effects the postpartum drop in estrogen would 
likely have resolved.86
Although an early naturalistic study suggested progesterone 
as a promising preventative therapy against recurrent postpar-
tum depression,89,90 the results of that study were contradicted 
by a subsequent double-blind, placebo-  controlled trial that 
found an increase in depressive symptoms in women treated 
with norethisterone enanthate, a synthetic progestogen.91 
In this study, 180 women were randomized to receive one 
depot injection of norethisterone enanthate or one injection 
of saline placebo within 48 hours after delivery and were fol-
lowed for three months. The investigators found that women 
who received the synthetic progestogen were more likely to 
develop depressive symptoms, more likely to have bleeding, 
and more likely to complain of exhaustion. A recent review 
of the above studies concluded that while the research on 
estrogen is promising but preliminary, there is no role for 
synthetic progestogens in the treatment of PPD, and that 
given the increased risk for depressive symptoms their use as 
contraception in this population is questionable.92
Other studies without control groups support an effect 
of estrogen in the treatment of postpartum depression. 
A small prevention study found that when a slow taper of 
estrogen therapy was administered immediately after birth 
to 11 women with a history of postpartum psychosis or 
depression only one woman suffered a relapse episode.93 
Another small study treated 23 women with severe post-
partum depression with sublingual 17-beta estradiol over 
8 weeks, and found remission of symptoms in 19 of the 
women, which the authors correlated with increased serum 
estrogen levels in the subjects.94 Both studies should be inter-
preted with caution, given the lack of a comparison group.
Although initial results for the use of estrogen in the 
treatment of postpartum depression are promising, additional 
methodologically sound studies are needed.86 Furthermore, 
estrogen therapy should not be used in women with an increased 
risk of thromboembolism. Treatment with gonadal steroids can 
interfere with lactation, which should be discussed with women 
prior to initiating therapy. Long-term use of estrogen therapy 
can cause endometrial hyperplasia and slightly elevates the risk 
of endometrial cancer; although this risk can be mitigated by 
co-administration of progesterone,86 the increase in depressive 
symptoms with progestogen seen in the Lawrie study compli-
cates the implementation of this strategy.
Psychological and psychosocial 
treatments for postpartum depression
Many mothers with postpartum depression are hesitant to 
take antidepressants due to concerns about infant exposure 
to medication through breast milk or concerns about   potential 
side effects,95 and therefore often prefer   psychological 
treatments.49,50,96 Although relatively few studies have 
  systematically investigated nonpharmacologic treatments 
for PPD, existing research supports the use of both psy-
chological treatments (specifically interpersonal ther-
apy,   cognitive-behavioral therapy, and psychodynamic International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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psychotherapy), as well as psychosocial interventions, 
such as nondirective counseling. A Cochrane meta-analysis 
of ten randomized controlled trials of psychosocial and 
  psychological treatments for postpartum depression 
  concluded that both psychosocial and psychological 
  interventions are effective in decreasing depression and are 
viable treatment options for postpartum depression.97
Interpersonal therapy (IPT)
Interpersonal therapy (IPT) is a time-limited treatment for 
major depression based on addressing the connection between 
interpersonal problems and mood,98 which frames depression 
as a medical illness occurring in a social context.99 In IPT, the 
patient and clinician select one of four   interpersonal problem 
areas (role transition, role dispute, grief, or interpersonal 
deficits) as a treatment focus. Over the course of the therapy 
(typically 12–20 weeks), strategies are pursued to assist 
patients in modifying problematic approaches to relationships 
and in building better social supports. IPT has been adapted 
to address problem areas relevant to postpartum depression 
such as the relationship between mother and infant, mother 
and partner, and transition back to work.100 The fact that IPT 
is both time-limited and problem-focused fits well with the 
demands of the postpartum mother.
Several studies, including one large-scale randomized 
controlled trial, have supported the effectiveness of IPT 
for treating postpartum depression. O’Hara and colleagues 
  randomized 120 women with postpartum depression to 
receive 12 weekly 60-minute individual sessions of manual-
ized IPT by a trained therapist versus control condition of a 
wait-list.101 The women who received IPT had a significant 
decrease in their depressive symptomatology (measured by 
Hamilton Depression Rating Scale and Beck Depression 
Inventory) as compared to the wait-list group, as well as 
  significant improvement in social adjustment scores. In 
another study by Clark et al 35 women with postpartum 
depression were assigned to individual IPT (12 sessions) 
versus mother–infant group therapy versus a wait-list 
condition.102 Both IPT and mother–infant group therapy were 
associated with greater reduction in depressive symptoms as 
compared to the wait-list conditions. Both studies support the 
effectiveness of IPT as a treatment for PPD, though there is 
not enough data to suggest a specific benefit to IPT compared 
with other therapeutic modalities.
Two small open studies have evaluated group IPT for 
postpartum depression. Klier et al conducted a pilot study 
in which 17 depressed women in two different groups 
received 9 weeks of group IPT and 3 individual sessions.103 
Depression scores on two rating scales decreased significantly 
during the course of treatment, and gains were maintained at 
6-month follow-up. However, there was a high attrition rate 
(6 out of 17), and the study was also limited by small sample 
size, lack of a control group, and lack of an independent rater. 
Similarly, Reay et al treated, in an open pilot trial, 18 women 
diagnosed with postpartum depression with 8 group IPT ses-
sions, as well as two individual and one partner session.104 
Depressive symptoms decreased significantly, and these gains 
were maintained at three months. Compared to the previous 
study, the drop-out rate was low, and authors speculated that 
this might be due to childcare provided. However, two-thirds 
of the study participants were receiving antidepressant therapy 
concomitantly, limiting interpretation of the effect of this 
group intervention. While it is difficult to make conclusions 
about efficacy based on this pilot data, the study authors 
suggest that advantages to group over individual IPT for 
postpartum depression might include increased social support, 
normalization of problems, development of interpersonal skills 
in a group setting that can be translated to outside relationships, 
and minimization of stigma associated with PPD.
Cognitive behavioral therapy (CBT)
Cognitive behavioral therapy (CBT), a well-studied and effec-
tive treatment for major depression,105 is based on the premise 
that both perceptions and behaviors are intimately linked to 
mood. CBT focuses on helping depressed patients to modify 
distorted patterns of negative thinking and to make behavioral 
changes that enhance coping and reduce distress.106 There 
have been several trials assessing CBT alone or with other 
interventions for the treatment of PPD. In a randomized con-
trolled psychotherapy-pharmacotherapy study, Appleby et al 
assigned 87 women with PPD to one of four conditions in a 
factorial design, varying based on treatment with either one or 
six sessions of CBT-based counseling, and treatment with flu-
oxetine or placebo.52 All four treatment groups had significant 
improvement in depressive symptoms. Women who received 
six CBT sessions versus one had greater decrease in depres-
sive symptoms. Six sessions of CBT plus placebo pill was 
as effective as treatment with fluoxetine plus one session of 
CBT, but there was no added benefit in the group receiving 6 
counseling sessions in combination with fluoxetine. It should 
be noted that the counseling sessions were delivered by 
briefly trained nonspecialists, and six sessions of CBT may 
not be a sufficient representation of a standard course of 
treatment. In another combination medication-CBT study, 
Misri et al randomized 35 women with PPD and comorbid 
anxiety either to paroxetine monotherapy or paroxetine and International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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12 weekly manualized CBT sessions with a psychologist.53 
While both groups had significant decreases in depressive 
symptoms, there were no significant differences between the 
two groups in response rates, time to remission or dose of 
medication required, suggesting no measurable added benefit 
to the CBT treatment in combination with an SSRI over the 
12 week study period, as consistent with Appleby’s findings. 
In a randomized controlled trial looking at the effectiveness 
of CBT versus a control condition, Prendergast and Austin 
assigned 37 women with PPD either to six weekly one-hour 
home-based CBT sessions delivered by early childhood 
nurses (ECNs) or to “ideal standard care”, which consisted 
of six weekly visits to ECNs in a clinic setting.107 Both 
groups with PPD had significant mood improvement, though 
there was a nonsignificant trend towards CBT being more 
effective at six-month follow-up. Among study limitations, 
ECNs administering CBT were not experienced therapists, 
though they received CBT training prior to the study and 
supervision throughout. Additionally, the control group more 
closely resembled a supportive psychotherapy rather than 
no-treament. These studies support CBT interventions as 
helpful in the treatment of PPD, though they do not support 
an additional benefit to CBT in combination with pharma-
cotherapy and do not clarify a specific benefit of CBT for 
this population in comparison with other treatments. Two of 
these studies also suggest a role for the training of nonmental-
health professionals in this modality.
Nondirective counseling
As compared with IPT or CBT, psychosocial interventions are 
unstructured and nonmanualized, and include nondirective 
counseling and peer support. Nondirective counseling (also 
known as “person-centered”) is based on the use of empathic 
and nonjudgmental listening and support. In the first notable 
study evaluating this intervention, Holden randomized 50 
women with PPD to 8 weekly nondirective counseling ses-
sions with a health visitor or routine primary care.108 A health 
visitor in the UK is a public health nurse who conducts home 
visits with pregnant and postpartum women. This study found 
that the rate of recovery from PPD for counseling (69%) was 
significantly greater than that of the control group (38%). In 
a similar study conducted in Sweden, Wickberg and Hwang 
randomized 31 women with PPD to receive six nondirective 
counseling sessions by child health clinic nurses or routine 
primary care.109 As in the Holden study, a significantly greater 
percentage of women in the treatment group (80%) had remis-
sion of depression than in the control group (25%). Study 
limitations include the removal of four study participants, 
two in each group, for more intensive mental health services 
due to illness severity.
Peer and partner support
Epidemiologic data as well as some prospective studies 
have consistently identified inadequate social support as a 
risk factor for developing postpartum depression,110–112 thus 
raising the possibility of interventions aimed at increasing 
social supports as treatment options for perinatal depression. 
In a prospective cohort of pregnant Chinese women, 
Xie et al112 found that low support in both the prenatal and 
postnatal time period was associated with increased risk for 
postpartum depression, with the highest risk for postpartum 
women who had low objective or practical support. The broad 
applicability of this study is limited by the demographics of 
its cohort (limited to married Chinese primiparous women 
without significant obstetric complications, rates of Caesarian 
delivery over 70%) and the use of a rating scale most vali-
dated in the Chinese population. However, the finding sug-
gests that tangible social support, such as assistance with 
caring for the newborn, may be particularly important and 
helpful in the treatment of postpartum depressed mothers.
In a pilot study, CL Dennis113 evaluated the effect of 
mother-to-mother support as delivered over the telephone 
on depressive symptomatology in a postpartum patient 
population identified as at high risk for PPD based on 
EPDS score .9. Standard postpartum care in addition to 
individualized telephone-based peer support resulted in a 
significant reduction in depressive symptoms at 8 weeks. 
More recently, in a larger randomized multisite trial, Dennis 
and colleagues demonstrated that high-risk postpartum 
women who received telephone-based peer support over 
12 weeks were at lower risk for developing PPD (as defined 
by EPDS .12) compared to a control group receiving usual 
care.114 Due in part to the telephone-based nature of the study, 
the investigators were unable to confirm the findings from 
rating scales with structured clinical interviews.
While poor partner support has been identified as an 
important risk factor for PPD,9 few studies have investigated 
the role of the partner or other family support in recovery 
from PPD. In one survey study, shared activities, problem-
focused information and assistance, and positive feedback 
from the partner decreased a mother’s likelihood of having 
depressive symptoms at 8 weeks postpartum.115 A qualita-
tive study examining factors identified by women who had 
recovered from PPD to be most important in their recovery 
found that “emotional support from partner”, “improved 
communication with partner”, “practical support from International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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partner”, and “emotional support from friends” were rated 
as “essential” to recovery.116 A small, nonblinded study by 
Misri et al examined the impact of partner support in the 
treatment of PPD.117 In this study, 29 women with PPD were 
randomized to receive 7 sessions of psychoeducation with 
(support arm) or without (control arm) their partners. Relative 
to the control group, women in the partner group had signifi-
cant reductions in depressive symptoms, while the partners in 
this group may also have had protective benefit on measures 
of general health. These studies do not provide enough data 
to recommend a specific partner-based intervention, but they 
do suggest that including the partner in the treatment of PPD 
may be of benefit for some women.
Comparisons of psychological  
and psychosocial treatments
Cooper et al designed a large study to assess the effects of 
different psychological interventions on PPD.118 A commu-
nity sample of 193 women with PPD were randomized to 
receive from weeks 8–18 postpartum routine primary care 
versus one of three treatment conditions: CBT, psychody-
namic psychotherapy, or nondirective counseling. All three 
treatments decreased depressive symptoms significantly 
as measured by EPDS at 4.5 months, in comparison to no 
treatment. Rates of remission from depression, as defined 
by DSM-III, were higher for those receiving psychodynamic 
therapy (71%) than CBT (57%) or nondirective counsel-
ing (54%). However, there were no differences among any 
of the groups at the 9 month assessment. Milgrom et al 
also undertook a study to compare different psychologi-
cal interventions for PPD.119 A community of 192 women 
with PPD were randomized to routine primary care or 12 
weeks of group-based CBT, or group-based or individual 
counseling utilizing supportive therapy techniques delivered 
by trained therapists. All three psychological interventions 
were superior to routine care in reducing symptoms of PPD. 
While there were no significant differences between coun-
seling and CBT, individual counseling was slightly more 
effective than group counseling. Finally, Morrell et al in a 
large, cluster randomized trial, looked at an intervention 
that trained health visitors to identify depressive symp-
toms in postnatal women and to deliver either a cognitive 
behavioral or nondirective “person-centered” approach 
involving up to eight sessions of individual counseling.120 
They compared this with usual care delivered by health 
visitors who did not receive this training, in conjunction 
with general practitioners. In this study, women who had 
an EPDS score $12 at 6 weeks postpartum were followed 
for 18 months. At 6 months, significantly more women in 
the control condition remained with elevated EPDS scores 
compared to both intervention groups, and the differences 
persisted at 12 months. There were no differences between 
the two counseling approaches. While the specific effective 
component of the intervention was unclear, this study does 
provide evidence that training in psychologically-informed 
approaches for non mental-health providers can signifi-
cantly enhance the care of depressed postnatal women.
A recent meta-analysis compared psychological and 
psychosocial interventions for PPD, including CBT, IPT, and 
nondirective counseling, as well as peer support.121 This study 
did not find any difference in effect size for any of these treat-
ments, and concluded that different types of psychological 
interventions seem equally effective for treatment of PPD.
In summary, both psychological and psychosocial 
interventions for PPD have shown benefit over no treatment 
or “usual care” in multiple studies. Further studies are 
needed to discriminate between the effectiveness of various 
psychological and psychosocial treatments for PPD and 
between group-based and individual modalities.
Other nonpharmacologic treatments  
for postpartum depression
Many women suffering from PPD and their healthcare 
providers may seek alternatives or adjuncts to standard 
psychological or pharmacologic treatments because of their 
concern about the effects of pharmacological treatment 
on breastfeeding,122 access to care, issues of stigma in the 
treatment of mental illness, limited effectiveness, or personal 
beliefs. In the following we have provided an overview of a 
variety of evidence-based nonpharmacologic treatments for 
postpartum depression.
electroconvulsive therapy
As with treatment-refractory major depression in the general 
population, electroconvulsive therapy (ECT) is an option 
for depressed postpartum women who do not respond to 
antidepressant medication or who have severe or psychotic 
symptoms. Data specific to this population are very limited. 
One small study of 5 women receiving ECT for refractory 
postpartum depression reported a 100% remission rate.123 
Apart from concerns regarding anesthesia and breast feeding, 
the use of ECT for postpartum depression does not differ 
from its use in major depression.124 Anesthetic agents used 
in ECT are typically rapidly metabolized, and risk of trans-
mission in breast milk can be minimized by timing breast 
feeding accordingly.International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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Bright light therapy
While bright light therapy was initially introduced as a treat-
ment for seasonal affective disorder, research has supported 
its effectiveness as a treatment for nonseasonal depression.125 
Light therapy presents an attractive option for the treatment 
of perinatal depression, as there are no known risks to the 
fetus or nursing infant. However, despite some encouraging 
preliminary data in antenatal depression,126 there is currently 
insufficient data on its effectiveness in the postpartum 
population. In one study,127 15 outpatient women with PPD 
were randomly assigned to receive bright light (10,000 lux, 
n = 10) or dim red light (600 lux, n = 5) daily for six weeks. 
This study was unable to elicit a specific treatment effect 
of the light therapy due to the small sample size, though 
both groups showed significant improvement over time on 
all measures of depression. Further studies are required to 
clarify the effectiveness of light therapy in the treatment of 
postpartum depression.
Omega-3 fatty acids
Omega-3 fatty acids have received specific attention in the 
treatment of perinatal depression, because of the known 
health benefits of these compounds for pregnant and 
postpartum women as well as some data showing positive 
effects on mood in the general population.128 Omega-3 fatty 
acids such as the eicosapentaenoic acid (EPA) and docosa-
hexaenoic acid (DHA) found in fish oils, are the key building 
blocks for the development of a baby’s central nervous system 
while in utero,129 and depletion of maternal omega-3 fatty 
acids occurs during pregnancy to facilitate this process.130 
One often-cited cross-national study131 evaluating major 
depression in the general population demonstrated that per 
capita fish consumption was inversely related to the risk of 
developing major depression. Further epidemiologic data 
support an association between low omega-3 intake from 
seafood and increased risk of high levels of depressive 
symptoms during pregnancy.132
Despite these epidemiologic associations, studies examin-
ing the use of omega-3 fatty acids for treatment of perinatal 
depression have had mixed results. Freeman et al conducted 
two pilot studies of omega-3 fatty acids as an intervention 
for perinatal depression; one was an open-label flexible-dose 
trial of a combination of EPA and DHA for the treatment 
of MDD during pregnancy,133 and the second trial assessed 
the efficacy of omega-3 fatty acids for postpartum depres-
sion in an 8-week randomized dose-ranging study.134 The 
outcome of the first trial showed a 40.9% mean decrease in 
depressive symptoms on the Edinburgh Postnatal Depression 
Scale. The second study, a randomized dose-ranging trial 
for postpartum depression found no significant difference 
between control and study group. Both studies were limited 
by their small sample sizes (n = 15 and 16, respectively) 
and their lack of a placebo group. A subsequent randomized 
placebo-controlled study investigating the combination of 
omega-3 fatty acids and supportive psychotherapy for the 
treatment of perinatal depression135 again demonstrated no 
significant difference between the omega-3 fatty acids and 
placebo, though participants in both groups experienced 
significant decreases in their depression rating scales. 
The benefits of supportive psychotherapy received by both 
groups may have limited the ability to detect a specific effect 
of omega-3 fatty acids. A subsequent small, randomized, 
double blind, placebo-controlled trial investigating omega-3 
fatty acids at a dose of 3.4 g per day as monotherapy for major 
depression during pregnancy136 demonstrated a benefit from 
this intervention. Although there was relatively high attrition 
in both groups, subjects receiving omega-3 fatty acids had 
significantly lower scores on depression rating scales as 
compared to the placebo group at the study end point.
In sum, omega-3 fatty acids may have therapeutic 
benefits for perinatal depression, but thus far most studies 
investigating this effect have been limited by small sample 
sizes. Some of these studies135 did establish that dietary intake 
of omega-3 fatty acids among participants was low prior to 
study involvement. Omega-3 fatty acids have clear health 
advantages for both the mother and for the developing fetus 
or nursing infant. Of note, omega-3 fatty acids can increase 
bleeding times at high doses, but according to a recent 
study,137 omega-3s at doses of 3–4 g/day produced no clini-
cally significant increase in bleeding times or in bleeding 
events in patients with cardiovascular disease already treated 
with anti-platelet agents.
Acupuncture and massage
Acupuncture is the ancient Chinese tradition of the insert-
ing and manipulating needles into various points on the 
body to treat pathologic processes and relieve pain. It has 
been investigated for the treatment of depression in the 
general population with mixed results,138 and has been 
increasingly investigated as adjunctive treatment in preg-
nancy for nausea, pain, breech presentation and induction 
of labor.139 There is no data about the use of acupuncture in 
postnatal depression, but one small pilot study by Manber 
et al compared the effectiveness of targeted acupuncture 
vs controls of a nontargeted acupuncture and massage in 
the treatment of pregnant depressed women.140 8 weeks of International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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an active acupuncture intervention targeted specifically for 
depression (treatments were standardized but individually 
tailored) significantly outperformed a massage intervention 
in terms of reduction of depressive symptom rating scales in 
depressed pregnant women. While there was no significant 
difference in symptom reduction between the targeted and 
control acupuncture treatments in this study, a more recently 
published larger randomized trial of acupuncture in pregnant 
women showed significant reduction in depressive symptoms 
in active treatment versus both control conditions.141 The 
authors caution that the study was not designed to assess the 
effectiveness of massage as a treatment for perinatal depres-
sion. It is not clear what the effects of antenatal or postnatal 
acupuncture are on postnatal depression. It should be noted 
that as acupuncture may have effects on induction of labor and 
lactation,138,142 women who wish to try acupuncture as a treat-
ment or adjunctive therapy for perinatal depression should be 
sure the practitioner is experienced in these issues.
Massage as treatment for perinatal depression has also 
been examined independently, and modalities include thera-
peutic massage, partner-delivered massage, and instruction in 
infant-massage in the postpartum period. Field et al looked 
at the effect of 10 sessions of massage versus 10 sessions 
of relaxation techniques in 32 adolescent inpatients with 
postnatal depression, and found a significant improvement 
in depression ratings in the massage group after session 10 
but not the relaxation group.143 There was no longer-term 
follow up, so the clinical implications of this study are lim-
ited. Another study looked at the effects of infant massage, 
and compared the effects of 15 minutes of rocking versus 
15 minutes of massage on 40 full-term infants between the 
ages of 1 and 3 months born to depressed mothers.144 They 
found multiple benefits for the infants in the massage group, 
including improvements in sleep patterns, interactions, 
crying, weight gain, and lower cortisol levels, though there 
was no measure of effects on maternal depression. Onozawa 
et al145 compared outcomes in mother–infant pairs who 
received 5 weekly sessions of infant massage classes plus 
a support group with mothers who were in a support group 
alone. Depression scores in both groups decreased without 
significant difference, but only the infant massage group 
showed statistically significant improvement in global rat-
ings of mother–infant interactions. However, there was high 
drop-out in this study, and significant improvement in the 
massage group occurred prior to the first class, suggesting 
nonspecific or anticipatory benefit. A subsequent trial with 
a similar design146 failed to demonstrate these same advan-
tages in mother–infant interactions after six sessions of infant 
massage compared to support groups alone, and depression 
scores in both groups again improved similarly. A more recent 
study investigated maternal massage therapy administered by 
the woman’s partner for 12 weeks147 in depressed pregnant 
women and found benefit in the massage group on indices of 
depression during late pregnancy and immediately postpar-
tum, as well as lower cortisol levels in mothers and neonates. 
However, the control condition was unspecified standard care, 
and as there was no longer term follow-up the impact of the 
intervention on PPD is unclear. In summary, massage in its 
various forms described above has few risks, and may have 
benefits for women and their infants, but its effectiveness as 
a treatment for PPD remains in question.
exercise
Several studies have investigated the role that exercise can 
play in alleviating postpartum depressive symptoms.148 A 
study by Da Costa et al looked at 88 women with PPD who 
were randomized to a 12-week, home-based exercise pro-
gram or usual care.149 There was a reduction in depression 
rating scales in the intervention group as compared to the 
usual care group post-treatment, though not at the 3-month 
follow-up. However, Ko et al150 investigated a low-intensity 
exercise program that was specifically designed and admin-
istered to women with postpartum fatigue and depression. 
There was no significant change in depression between the 
treatment group and the control group. Despite the limited 
evidence of efficacy for treatment of PPD,151 the UK National 
Institute for Health and Clinical Excellence (NICE)152 
has recommended in their antenatal and postnatal mental 
health guidelines that health professionals should consider 
exercise as a management strategy in women experiencing 
mild-to-moderate depression. A review of the effects of 
exercise on PPD defined “feasible and effective” exercise 
as: moderate-intensity activities for at least 30 minutes per 
day, five days of the week, including walking in the form of 
“pram pushing”.153
Conclusion
Postpartum depression is a major international public health 
problem that affects at least 1 in 8 mothers and their children 
in the year after childbirth worldwide. PPD may be more 
common and may be associated with more morbidity for both 
mothers and children in resource-poor countries. PPD has 
been associated with significant negative effects not only on 
depressed women themselves, but on the physical, cognitive 
and emotional development of their children. Early detec-
tion and intervention are important in mitigating these risks. International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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There are validated and easily administered screening tools 
for PPD available in many languages, such as the Edinburgh 
Postnatal Depression Scale; most experts recommend screen-
ing women for PPD 4–6 weeks after delivery.
Psychopharmacologic treatment of PPD is complicated 
by both known and unknown risks of medication in breast 
milk. There have been few medication trials specifically 
evaluating the effectiveness of antidepressant medication or 
ECT for postpartum depression, but the available evidence 
suggests that medications typically used to treat major 
depression in the general population are equally effective in 
postpartum depression. All medications pass into breast milk, 
though the extent of passage varies considerably between 
drugs, and sertraline, paroxetine and nortriptyline currently 
appear to have the best safety profiles in breastfeeding. There 
have been case reports of adverse effects in nursing infants of 
antidepressant medication in breast milk, but the advantages 
of breastfeeding to the mother and infant may outweigh the 
risks of exposure. Exposed infants should be monitored 
for any acute behavioral changes. However, the long-term 
risks of medication exposure to the infant remain unknown. 
Most experts recommend that the choice of medication in 
the postpartum should be based first on known efficacy for 
an individual woman, and that known milk-plasma ratios 
should be a secondary consideration unless a patient is 
treatment-naïve. Some studies suggest that estrogen may be 
an effective agent for treatment, prevention or augmenta-
tion in depressed postpartum women; however data remains 
limited and there are significant health considerations with 
hormonal intervention.
Psychological treatments for PPD are often the treatment 
of choice for women, as they are effective for the treatment 
of depressive symptoms and do not involve the risks of 
exposure to medications. Research supports both psycho-
therapy and other psychosocial interventions as effective in 
mitigating symptoms of PPD. Interpersonal psychotherapy, 
cognitive behavioral therapy, psychodynamic psychotherapy 
and other supportive interventions such as telephone-based 
peer support, counseling by a health visitor, and partner 
support have also shown benefit over wait-list or usual care 
controls.
Other nonpharmacologic interventions that have been 
studied in the treatment of PPD include bright light therapy, 
acupuncture, massage, omega-3 fatty acid supplementation, 
and exercise. Data on the effectiveness of these modalities 
in decreasing maternal depressive symptoms is limited, but 
these interventions have minimal risks and may have health 
benefits for both mother and infant.
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